search
diabetes patients
Trends
- 1Stopping GLP-1 drugs may raise heart attack and stroke riskโStopping GLP-1 drugs may raise heart attack and stroke risk, study finds
A new study finds that people who stop taking GLP-1 weight-loss and diabetes drugs, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings suggest the cardiovascular benefits of these medications depend on continued use, raising questions about how patients should manage long-term treatment.
- 2Doctors warn GLP-1 drug users face heat wave health risksโผAmid heat wave, doctors warn of health risks for people taking GLP-1 drugs
Doctors are warning that people taking GLP-1 weight-loss and diabetes drugs such as Ozempic may face heightened health risks during the current heat wave. Concerns center on dehydration, as the medications can suppress thirst and appetite, potentially leaving users vulnerable to heat exhaustion and related complications. Patients are being advised to drink water regularly and take precautions in high temperatures as extreme heat persists across many regions.
- 3Pancreatic Cells One Genetic Tweak From Treating DiabetesโผSome Pancreatic Cells Are Just One Genetic Tweak Away From Treating Diabetes https:// fed.brid.gy/r/https://www.wire d.c
New research suggests some pancreatic cells could be converted into insulin-producing cells with a single genetic modification, offering a promising avenue for diabetes treatment. The findings, reported by Wired, point to the potential of reprogramming existing cells to restore insulin function in patients. Scientists and health watchers are sharing the story as a possible step toward new therapies for the disease.
- 4The End of Insulin Injections? Scientists Push Needle-Free MedicineโผThe End of Insulin Injections? How Scientists Are Making Medicine Needle-Free
Scientists are developing needle-free ways to deliver medicine, including insulin, with the goal of replacing traditional injections for millions of patients, particularly people with diabetes. The work, highlighted by National Geographic, covers new technologies that could deliver drugs through the skin or other routes without needles. If successful, the approach could reduce pain and needle anxiety for patients who need daily injections.
- 5Doctors weigh in on the Ozempic microdosing trendโผIs microdosing Ozempic safe? An obesity medicine doctor on the trend, the risks, and when a low dose makes sense
An obesity medicine doctor is addressing the growing trend of microdosing Ozempic, the diabetes drug widely used for weight loss, explaining the safety concerns and potential risks of taking lower-than-standard doses. The doctor notes there are limited situations where a low dose may be appropriate, but warns patients against adjusting medication on their own without medical supervision.
- 6Strict blood sugar control may carry hidden costs, study findsโDiabetes study finds keeping blood sugar too steady may come at a price
New research into diabetes suggests that keeping blood sugar levels extremely steady, long considered the gold standard of management, may come with drawbacks. The findings challenge the assumption that tighter is always better for glucose control, prompting debate among clinicians and patients about how aggressively blood sugar should be stabilised and what trade-offs tight control may involve.
- 7Study links GLP-1 drugs in children to nutritional deficienciesโInteractive: Study links GLP-1 use in children to nutritional deficiencies
A new study has connected the use of GLP-1 weight-loss and diabetes medications in children with nutritional deficiencies, according to Scripps News, which published an interactive report on the findings. The drugs, widely prescribed to minors amid rising childhood obesity rates, may leave young users short of key nutrients. The findings add to ongoing debate over the safety and supervision of GLP-1 treatment in pediatric patients.
- 8Israeli startup wins FDA clearance for injection-based diabetes appโIsraeli startup develops injection-based diabetes app, receives FDA clearance
An Israeli startup has received US Food and Drug Administration clearance for an app designed to support people managing diabetes with injections. The digital tool is aimed at helping patients track and handle their insulin treatment more effectively. The clearance marks a regulatory milestone for the young company, and coverage in Israeli media highlights it as another example of the country's health-tech sector gaining traction abroad.
- 9Nutritional Deficiencies Reported in Youth on GLP-1 DrugsโผNutritional Deficiencies Seen in Youth Taking GLP-1 Receptor Agonists
New reporting highlights that young people taking GLP-1 receptor agonists, a class of drugs widely used for weight management and diabetes, are showing nutritional deficiencies. Clinicians are being advised to monitor nutrient intake in pediatric and adolescent patients on these medications, as appetite suppression may reduce overall consumption of essential vitamins and minerals during critical growth years.
- 10FDA approves Onswik, a once-weekly insulin for type 2 diabetesโThe FDA approved Onswik, a once-weekly insulin for type 2 diabetes, but not for type 1. What the trials showed and the s
The FDA has approved Onswik, a once-weekly insulin intended for adults with type 2 diabetes. It was not approved for type 1 diabetes. Coverage highlights what the clinical trials showed about effectiveness and the side effects patients should know about. The approval is drawing attention as a potential convenience shift for diabetes management, reducing injections from daily to weekly.
- 11Heart and Kidney Problems Rise Over Time in Type 2 DiabetesโผHeart and Kidney Problems in Type 2 Diabetes Patients Increase with Time
New coverage reports that heart and kidney complications in patients with type 2 diabetes increase as the disease progresses over time. The finding underscores the cumulative toll of diabetes on cardiovascular and renal health and highlights the importance of long-term monitoring and management of blood sugar, blood pressure and kidney function in affected patients.